Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

RTE Late Late Show viewers have praised Dearbhla Mescal after she opened up about a “dark time” in her life. The Irish author joined Co Down host Patrick Kielty on the hit chat show ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

Baraka is no stranger to the national spotlight. After he was arrested at Delaney Hall last year when McIver, Menendez and Watson Coleman sought to conduct an oversight visit, his profile as a ...

Jazz musician whose virtuosic abilities with the clarinet and tenor saxophone straddled traditional and modern jazz ...

Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Colon cancer survivor Vivian Chee has had three lung surgeries since 2021 but continues to keep fit. Read more at straitstimes.com. Read more at straitstimes.com.